Feed VLA.PA
VL

Valneva SE VLA.PA PAR · Healthcare · France

2.35 € -3.96% -0.10 €

Summary

14 / 100 · Bulios Score

What speaks for it

None of the indicators we track stands out on the positive side.

What to watch

  • Revenue fell by 22% a year over the last 3 years.
  • The company made a loss over the last 12 months.
  • The share price is above the Bulios Fair Price.
  • It passes only 1 of the 9 points of the Piotroski financial health test.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks expensive
Bulios Fair Price
Overvalued Price today 2.35 €

By our assumptions the business is worth less than its shares cost today.

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

The company made a loss over the last 12 months, so there is no profit to set the price against.

Valuation in detail

Is it growing?

It is shrinking

Revenue (EUR)

Diluted EPS (EUR)

  • Analyst estimate

Revenue grew by 9.6% a year over 5 years. Over the last 3 years it fell by 22% a year. For the next fiscal year analysts expect revenue to fall by 13%.

Growth in detail

Does it make money?

Poorly

Over the last 12 months it made a loss of 157.7M €.

Profitability in detail

Is it financially healthy?

Debt is a burden

Over the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

Mildly positive

No analyst has published a price target.

100% of the analysts recommend buying.

Analysts in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy